Morning Briefing
Summaries of health policy coverage from major news organizations
Theranos' Downfall Serves As Cautionary Reminder To Silicon Valley Investors
If something seems too good to be true, it just might be. Don't buy into the hype. Pay attention to red flags. These are just some of the lessons investors may take away when they evaluate what happened with the blood-testing startup.
Silicon Valley鈥檚 best-known venture investors have emerged largely unscathed from the rapid descent of Theranos Inc., but the decline offers a cautionary tale for a community that bets big on visionary founders touting revolutionary technology. ... Silicon Valley investors say Palo Alto, Calif.-based Theranos鈥攚hich was valued at $9 billion in a 2014 funding round鈥攐ffers lessons about the importance of oversight and due diligence in the venture-capital business, which bets sometimes on nothing more than an idea. (Winkler, 7/13)
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
